Half-year report · Q2
7776.TEDINET S100WJ5L
Period2025-01-01 → 2025-06-30
Filed2025-08-14
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥37m | 2025-01-01 → 2025-06-30 | Standalone | Net sales |
| Revenue | ¥193m | 2024-01-01 → 2024-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥76m | 2024-01-01 → 2024-06-30 | Standalone | Net sales |
| Operating income | −¥623m | 2025-01-01 → 2025-06-30 | Standalone | Operating income |
| Operating income | −¥464m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Ordinary income | −¥624m | 2025-01-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥848m | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥463m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥651m | 2025-01-01 → 2025-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥473m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Net income | −¥651m | 2025-01-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | −¥860m | 2024-01-01 → 2024-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥474m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Total assets | ¥1.9bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥2.4bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥2.4bn | at 2024-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥400m | at 2025-06-30 | Standalone | Liabilities |
| Total liabilities | ¥270m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.5bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥2.1bn | at 2024-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2025-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2025-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-12-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥473m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥866m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥405m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥717,000 | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥18m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | −¥4m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥855m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥422m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-18.78 | 2025-01-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.72 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.74 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 78.5% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.4% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 34,666,419 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 34,666,419 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 33,447,119 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥115m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥449m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥35m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥35m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥59m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥37m |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥37m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥508m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥113m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥332m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥75m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥75m |
| jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥19m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥76m |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥76m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | −¥351m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 429
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社セルシード | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都江東区青海二丁目５番10号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Description of fact that consolidated financial statements have not been prepared financial information | CurrentYTDDuration | Original text (Japanese)当社は子会社がありませんので、中間連結財務諸表を作成しておりません。 | |
| Quarterly balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant_NonConsolidatedMember | Text · Plus | |
| Notes regarding research and development expenses (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes segment information etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes revenue recognition quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |